Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Nanjing
Clinical trial register · China

Clinical Trials in Nanjing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 07 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 44 Beijing 38 Shanghai 26 Fuzhou 20 Hangzhou 18
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou44 Beijing38 Shanghai26 Fuzhou20 Hangzhou18
All 57 locations
Target enrolment
to

Trials with a site in Nanjing

17 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
West China Hospital
Not applicable
60
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
2026-12-01
Not yet open
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
690
Nanjing, Shanghai
2026-11
Not yet open
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
600
Nanjing
2026-09
Recruiting
Lepu Biopharma Co., Ltd.
Phase 1/2
160
Beijing, Fuzhou, Zhengzhou, Nanjing, Tianjin, Lishui
2026-04-08
Recruiting
Peking Union Medical College Hospital
Phase 2
158
Beijing, Nanjing, Xuzhou
2025-12-24
Not yet open
The First Affiliated Hospital with Nanjing Medical University
Phase 2
48
Nanjing
2025-08-11
Active, closed
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Recruiting
Immunotherapy for Hepatocellular Carcinoma
NCT06241326Hepatocellular Carcinoma, Immunotherapy
The First Affiliated Hospital with Nanjing Medical University
Observational
11,000
Nanjing
2024-03-01
Recruiting
Zhongda Hospital
Not applicable
5
Nanjing
2024-02-01
Recruiting
Zhongda Hospital
Not applicable
188
Beijing, Nanjing
2023-12-19
Not yet open
Qilu Pharmaceutical Co., Ltd.
Phase 2/3
668
Nanjing, Shanghai
2023-09-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 3
130
Nanjing
2023-01-31
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
100
Nanjing
2022-05-01
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Active, closed
Exelixis
Phase 3
837
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2018-06-10
Active, closed
MedImmune LLC
Phase 2
433
Hangzhou, Nanjing, Shanghai
2015-10-19
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-china/city/nanjing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 07 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 17 of those studies with a site in Nanjing that also match the filters currently applied.

How many clinical trials are recruiting in Nanjing?

8 of the 17 studies on this page are recruiting new participants as of the 07 Nov 2026, 03:17 UTC sync. A further 5 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nanjing), 17 studies
PhaseStudiesRecruitingShare
Phase 35229.4%
Not applicable4323.5%
Phase 24123.5%
Phase 1/22111.8%
Observational115.9%
Phase 2/3105.9%

Most active sponsors

Lead sponsors with the most studies (Nanjing)
Lead sponsorStudiesRecruiting
The First Affiliated Hospital with Nanjing Medical University43
Zhongda Hospital22
Akeso11
Ascentawits Pharmaceuticals, Ltd10
AstraZeneca10
Exelixis10
Lepu Biopharma Co., Ltd.11
MedImmune LLC10
Peking Union Medical College Hospital11
Qilu Pharmaceutical Co., Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.